We are live on ! Find out more
KCA

KVP Capital Advisors Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+25.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$2.34M
Cap. Flow
-$18.6M
Cap. Flow %
-13.67%
Top 10 Hldgs %
57.41%
Holding
38
New
6
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$5.26M
2
AVBP icon
ArriVent BioPharma
AVBP
+$3.01M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$2.31M
4
DSGN icon
Design Therapeutics
DSGN
+$2.31M
5
ARTV
Artiva Biotherapeutics
ARTV
+$1.82M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$23.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$5.25M
3
RVMD icon
Revolution Medicines
RVMD
+$3.91M
4
TVTX icon
Travere Therapeutics
TVTX
+$2.31M
5
SLNO
Soleno Therapeutics
SLNO
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
26
Travere Therapeutics
TVTX
$6.19B
$2.22M 1.63%
39,000
-52,000
-57% -$2.31M
ZURA icon
27
Zura Bio
ZURA
$548M
$2.2M 1.62%
373,128
– –
ARTV
28
Artiva Biotherapeutics
ARTV
$542M
$1.94M 1.42%
+200,000
New +$1.82M
NKTR icon
29
Nektar Therapeutics
NKTR
$2.48B
$1.88M 1.38%
26,900
– –
CMPX icon
30
Compass Therapeutics
CMPX
$432M
$1.69M 1.24%
771,000
+271,000
+54% +$800K
CABA icon
31
Cabaletta Bio
CABA
$529M
$1.57M 1.15%
505,431
– –
VERA icon
32
Vera Therapeutics
VERA
$2.46B
$1.4M 1.03%
32,700
– –
EOLS icon
33
Evolus
EOLS
$587M
$1.04M 0.76%
+150,000
New +$886K
CELC icon
34
Celcuity
CELC
$4.33B
$418K 0.31%
4,000
– –
YARW
35
Yarrow Bioscience
YARW
$98.8M
$326K 0.24%
10,011
– –
RVMD icon
36
Revolution Medicines
RVMD
$44.6B
– –
-40,200
Closed -$3.91M
SLNO
37
DELISTED
Soleno Therapeutics
SLNO
– –
-59,700
Closed -$2M
TERN
38
DELISTED
Terns Pharmaceuticals
TERN
– –
-440,000
Closed -$23.2M
1
2

Similar funds

RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
SCM
Sidoxia Capital Management Newport Beach, California $136M AUM
VSCP
Vesey Street Capital Partners New York $136M AUM 6.83% 1-Year Est. Return

KVP Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, KVP Capital Advisors held 38 positions worth $136M, up 1.7% from $134M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

KVP Capital Advisors withdrew a net $18.6M in Q2 2026, closing 3 positions and reducing 2 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $23.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, KVP Capital Advisors opened a new position in Tandem Diabetes Care worth $4.54M.

  • KVP Capital Advisors's largest Q2 2026 buy was Tandem Diabetes Care: 301,000 shares worth $4.54M.
  • KVP Capital Advisors added most to Erasca in Q2 2026, an estimated $1.64M increase.
  • KVP Capital Advisors's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.25M.
  • KVP Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $23.2M.
  • KVP Capital Advisors's ten largest holdings make up 57% of its $136M portfolio in Q2 2026.
  • KVP Capital Advisors opened 6 new positions and closed 3 in Q2 2026.
  • KVP Capital Advisors's portfolio value rose 1.7% quarter-over-quarter to $136M.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.